FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551829042> ?p ?o ?g. }

• W1551829042 endingPage "1936" @default.
• W1551829042 startingPage "1925" @default.
• W1551829042 abstract "This study was undertaken to explore the potential of new therapeutic approaches designed to reactivate cell death pathways in apoptosis‐refractory gliomas and to characterize the underlying molecular mechanisms of this reactivation. Here we investigated the sensitivity of a panel of glioma cell lines (U87, U251, U343, U373, MZ‐54, and MZ‐18) to apoptosis induced by the death receptor ligand tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL), TRAIL in combination with gamma irradiation, and TRAIL in combination with proteasome inhibitors (MG132 and epoxomicin). Analysis of these six glioma cell lines revealed drastic differences in their sensitivity to these treatments, with two of the six cell lines revealing no significant induction of cell death in response to TRAIL alone. Interestingly, the proteasome inhibitors MG132 and epoxomicin were capable of potentiating TRAIL‐induced apoptosis in TRAIL‐sensitive U87 and U251 cells and of reactivating apoptosis in TRAIL‐resistant U343 and U373 cells. In contrast, gamma irradiation had no synergistic effects with TRAIL in the two TRAIL‐resistant cell lines. RNA interference against death receptor 5 (DR5) revealed that reactivation of TRAIL‐induced apoptosis by proteasome inhibitors depended on enhanced transcription and surface expression of DR5. Transient knockdown of the transcription factor GADD153/C/EBP homologous protein and application of the synthetic c‐Jun N‐terminal kinase inhibitor SP600125 indicated that enhanced DR5 expression occurred independently of GADD153/C/EBP homologous protein, but required activation of the c‐Jun N‐terminal kinase/c‐Jun signaling pathway. Novel therapeutic approaches using TRAIL or agonistic TRAIL receptor antibodies in combination with proteasome inhibitors may represent a promising approach to reactivate apoptosis in therapy‐resistant high‐grade gliomas." @default.
• W1551829042 created "2016-06-24" @default.
• W1551829042 creator A5031963906 @default.
• W1551829042 creator A5039173577 @default.
• W1551829042 creator A5075015717 @default.
• W1551829042 creator A5075817512 @default.
• W1551829042 creator A5079875617 @default.
• W1551829042 date "2008-03-13" @default.
• W1551829042 modified "2023-10-18" @default.
• W1551829042 title "Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis" @default.
• W1551829042 cites W1536266814 @default.
• W1551829042 cites W1750631750 @default.
• W1551829042 cites W1759028523 @default.
• W1551829042 cites W1965727325 @default.
• W1551829042 cites W1970367033 @default.
• W1551829042 cites W1984107615 @default.
• W1551829042 cites W1990251516 @default.
• W1551829042 cites W2001817269 @default.
• W1551829042 cites W2005853424 @default.
• W1551829042 cites W2008744347 @default.
• W1551829042 cites W2012880829 @default.
• W1551829042 cites W2016446012 @default.
• W1551829042 cites W2021501434 @default.
• W1551829042 cites W2028513543 @default.
• W1551829042 cites W2033150364 @default.
• W1551829042 cites W2039973219 @default.
• W1551829042 cites W2045343790 @default.
• W1551829042 cites W2054473882 @default.
• W1551829042 cites W2054717287 @default.
• W1551829042 cites W2055905844 @default.
• W1551829042 cites W2056205420 @default.
• W1551829042 cites W2058473971 @default.
• W1551829042 cites W2067653691 @default.
• W1551829042 cites W2071018175 @default.
• W1551829042 cites W2079108606 @default.
• W1551829042 cites W2082617142 @default.
• W1551829042 cites W2084733813 @default.
• W1551829042 cites W2091501978 @default.
• W1551829042 cites W2096735689 @default.
• W1551829042 cites W2106578289 @default.
• W1551829042 cites W2114998237 @default.
• W1551829042 cites W2121001769 @default.
• W1551829042 cites W2122684890 @default.
• W1551829042 cites W2144037068 @default.
• W1551829042 cites W2152290005 @default.
• W1551829042 cites W2322684614 @default.
• W1551829042 cites W26559748 @default.
• W1551829042 cites W4239943549 @default.
• W1551829042 doi "https://doi.org/10.1111/j.1742-4658.2008.06351.x" @default.
• W1551829042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18341587" @default.
• W1551829042 hasPublicationYear "2008" @default.
• W1551829042 type Work @default.
• W1551829042 sameAs 1551829042 @default.
• W1551829042 citedByCount "46" @default.
• W1551829042 countsByYear W15518290422012 @default.
• W1551829042 countsByYear W15518290422013 @default.
• W1551829042 countsByYear W15518290422014 @default.
• W1551829042 countsByYear W15518290422015 @default.
• W1551829042 countsByYear W15518290422016 @default.
• W1551829042 countsByYear W15518290422017 @default.
• W1551829042 countsByYear W15518290422018 @default.
• W1551829042 countsByYear W15518290422019 @default.
• W1551829042 countsByYear W15518290422020 @default.
• W1551829042 countsByYear W15518290422021 @default.
• W1551829042 crossrefType "journal-article" @default.
• W1551829042 hasAuthorship W1551829042A5031963906 @default.
• W1551829042 hasAuthorship W1551829042A5039173577 @default.
• W1551829042 hasAuthorship W1551829042A5075015717 @default.
• W1551829042 hasAuthorship W1551829042A5075817512 @default.
• W1551829042 hasAuthorship W1551829042A5079875617 @default.
• W1551829042 hasConcept C104317684 @default.
• W1551829042 hasConcept C127561419 @default.
• W1551829042 hasConcept C153911025 @default.
• W1551829042 hasConcept C173396325 @default.
• W1551829042 hasConcept C17991360 @default.
• W1551829042 hasConcept C185592680 @default.
• W1551829042 hasConcept C190283241 @default.
• W1551829042 hasConcept C203014093 @default.
• W1551829042 hasConcept C27740335 @default.
• W1551829042 hasConcept C2776148510 @default.
• W1551829042 hasConcept C2778227246 @default.
• W1551829042 hasConcept C2778367456 @default.
• W1551829042 hasConcept C2778506107 @default.
• W1551829042 hasConcept C31573885 @default.
• W1551829042 hasConcept C502942594 @default.
• W1551829042 hasConcept C54355233 @default.
• W1551829042 hasConcept C55493867 @default.
• W1551829042 hasConcept C62478195 @default.
• W1551829042 hasConcept C81885089 @default.
• W1551829042 hasConcept C86803240 @default.
• W1551829042 hasConcept C95444343 @default.
• W1551829042 hasConceptScore W1551829042C104317684 @default.
• W1551829042 hasConceptScore W1551829042C127561419 @default.
• W1551829042 hasConceptScore W1551829042C153911025 @default.
• W1551829042 hasConceptScore W1551829042C173396325 @default.
• W1551829042 hasConceptScore W1551829042C17991360 @default.
• W1551829042 hasConceptScore W1551829042C185592680 @default.
• W1551829042 hasConceptScore W1551829042C190283241 @default.

• next